Want to see NVOS full AI Analyst Report?
NVOS Stock Chart & Stats
$0.06
<$0.01(4.44%)
At close: 4:00 PM EST
$0.06
<$0.01(4.44%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.06
Previous CloseN/A
Volume66.19K
Average Volume (3M)46.26K
Market Cap
$69.06K
Enterprise Value$3.91M
Total Cash (Recent Filing)$844.58K
Total Debt (Recent Filing)$4.71M
Price to Earnings (P/E)―
Beta1.20
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding19,730,247
10 Day Avg. Volume11,807
30 Day Avg. Volume46,255
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.38
Price to Sales (P/S)0.43
P/FCF Ratio-2.48
Enterprise Value/Market Cap56.69
Enterprise Value/Revenue0.29
Enterprise Value/Gross Profit0.68
Enterprise Value/Ebitda-0.59
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthConsistent revenue growth indicates expanding market reach and product adoption, which can support long-term business sustainability.
Conservative LeverageA low debt-to-equity ratio suggests conservative leverage, providing financial flexibility and reducing risk of financial distress.
Strategic PartnershipsStrategic partnerships enhance market presence and distribution channels, potentially driving revenue and market share growth.
Bears Say
Negative Profit MarginsNegative profit margins indicate operational inefficiencies and high costs, which can hinder profitability and long-term financial health.
Negative Cash FlowConsistently negative cash flow raises concerns about the company's ability to sustain operations without additional financing.
Declining Equity RatioA declining equity ratio reflects reduced financial stability, potentially limiting the company's ability to invest in growth opportunities.
Novo Integrated Sciences News
NVOS FAQ
What was Novo Integrated Sciences’s price range in the past 12 months?
Novo Integrated Sciences lowest stock price was <$0.01 and its highest was $0.06 in the past 12 months.
What is Novo Integrated Sciences’s market cap?
Novo Integrated Sciences’s market cap is $69.06K.
When is Novo Integrated Sciences’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Novo Integrated Sciences’s earnings last quarter?
Currently, no data Available
Is Novo Integrated Sciences overvalued?
According to Wall Street analysts Novo Integrated Sciences’s price is currently Overvalued.
Does Novo Integrated Sciences pay dividends?
Novo Integrated Sciences does not currently pay dividends.
What is Novo Integrated Sciences’s EPS estimate?
Novo Integrated Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Novo Integrated Sciences have?
Novo Integrated Sciences has 19,730,247 shares outstanding.
What happened to Novo Integrated Sciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Novo Integrated Sciences?
Currently, no hedge funds are holding shares in NVOS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Novo Integrated Sciences
Novo Integrated Sciences, Inc. (NVOS) delivers a diverse array of primary healthcare services and related products through its two primary operational segments: Healthcare Services and Product Manufacturing and Development. The company's extensive service portfolio includes various therapeutic approaches such as physiotherapy, chiropractic care, manual manipulation, occupational therapy, and massage therapy. They also offer specialized treatments like acupuncture, functional dry needling, chiropody, and advanced rehabilitation for stroke, traumatic brain injuries, and other neurological conditions. Additionally, NVOS provides kinesiology, vestibular therapy, concussion management, and baseline testing, alongside unique programs like trauma-sensitive yoga and meditation for brain injury recovery and PTSD. Women's pelvic health, sports medicine, assistive device provision, dietetics, holistic nutrition, fall prevention education, sports team conditioning, and private personal training are also part of their offerings. Novo Integrated Sciences, Inc. is dedicated to the assessment, diagnosis, treatment, pain management, rehabilitation, education, and prevention of a wide range of orthopedic, musculoskeletal, sports injury, and neurological conditions. These services are provided across all age demographics, from pediatric and adult patients to geriatric populations. For older adults, the company offers comprehensive eldercare physiotherapy within long-term care homes, retirement communities, and through community-based home care. This includes group exercise classes and fall prevention initiatives, alongside services at outpatient clinics. Similarly, occupational therapy services for the elderly are extended to retirement communities and long-term care facilities. Beyond direct care, the company incorporates medical technology, offering telemedicine consultations and remote patient monitoring. It also actively develops and distributes bespoke health and wellness product solutions. NVOS operates a network of 16 wholly-owned clinics. Established in 2000, the company is headquartered in Bellevue, Washington, and operates as a subsidiary of ALMC-ASAP Holdings, Inc.
Technical Analysis
American Shared Hospital Services
―
Concord Medical Services
―
Cryo-Cell International
―
P3 Health Partners
―
Mobile-health Network Solutions Class A
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.07% Other Institutional Investors
99.93% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---










